Perspective Therapeutics (NYSEAMERICAN:CATX) Earns Outperform Rating from Lifesci Capital

Lifesci Capital restated their outperform rating on shares of Perspective Therapeutics (NYSEAMERICAN:CATX) in a research note released on Monday, Zacks.com reports. Lifesci Capital also issued estimates for Perspective Therapeutics’ FY2024 earnings at ($0.12) EPS and FY2025 earnings at ($0.14) EPS.

CATX has been the topic of several other reports. B. Riley lifted their price objective on shares of Perspective Therapeutics from $1.20 to $1.70 and gave the stock a buy rating in a research report on Tuesday, April 9th. Oppenheimer reiterated an outperform rating and set a $1.50 price target (up previously from $1.20) on shares of Perspective Therapeutics in a report on Monday, April 1st.

Perspective Therapeutics Price Performance

CATX stock opened at 1.76 on Monday. The company has a quick ratio of 1.07, a current ratio of 1.07 and a debt-to-equity ratio of 0.02. The company has a market cap of $1.03 billion, a P/E ratio of -17.60 and a beta of 1.43. Perspective Therapeutics has a 12 month low of 0.21 and a 12 month high of 1.90.

Insider Transactions at Perspective Therapeutics

In related news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the stock in a transaction dated Wednesday, March 6th. The shares were acquired at an average price of 0.95 per share, for a total transaction of 57,409,487.05. Following the completion of the purchase, the insider now owns 116,773,394 shares in the company, valued at approximately 110,934,724.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 3.52% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Perspective Therapeutics

Institutional investors have recently bought and sold shares of the business. Perkins Capital Management Inc. acquired a new position in shares of Perspective Therapeutics in the 3rd quarter worth approximately $731,000. HighTower Advisors LLC bought a new stake in Perspective Therapeutics in the third quarter valued at $314,000. Taylor & Morgan Wealth Management LLC raised its stake in Perspective Therapeutics by 8.7% during the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock worth $251,000 after acquiring an additional 50,000 shares in the last quarter. Bank of New York Mellon Corp bought a new position in shares of Perspective Therapeutics during the third quarter valued at $42,000. Finally, RIA Advisory Group LLC boosted its stake in shares of Perspective Therapeutics by 1,313.4% in the 1st quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock valued at $127,000 after purchasing an additional 99,293 shares in the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.